Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.4%
    Check dated 2025-04-30T13:53:29.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Difference
    0.3%
    Check dated 2025-04-23T08:19:52.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the removal of detailed information about a clinical study comparing magrolimab and venetoclax for treating TP53 mutant acute myeloid leukemia, while adding new drug names and identifiers related to the study.
    Difference
    21%
    Check dated 2025-04-16T01:38:29.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The page has updated its version from v2.14.3 to v2.14.4 and removed a date of 2025-03-25 while adding two new dates: 2025-01-09 and 2025-02-05.
    Difference
    0.5%
    Check dated 2025-04-08T20:05:39.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version (v2.14.3) and the removal of estimated dates for updates, providing more accurate information regarding the posting of results and updates.
    Difference
    0.3%
    Check dated 2025-04-01T13:48:45.000Z thumbnail image
  7. Check
    45 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2025-03-25T06:44:22.000Z thumbnail image

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.